• News
  • SAN DIEGO
  • BioTech

Halozyme stock dips on share offering

Shares in San Diego’s Halozyme Therapeutics (Nasdaq: HALO) dropped sharply on Wednesday after the company announced it was launching a new offering of 7.7 million shares priced at $13 per share, compared to Wednesday’s opening price of $13.55.

The stock dropped as low as $12.78, although it has since rebounded to around $13.20, even though the offering, which will close on Feb. 10, gives underwriters a 30-day option to buy an additional 1.2 million shares at the lower price.

Some investors may have been assuaged by a report by analysts at the Prohost Biotechnology newsletter who say the stock offering will be worthwhile over the long haul. The money will be used to help fund Phase 2 testing of the company’s PEGPH20 program, aimed at treating pancreatic, breast, colon, prostate and other cancers.

“Is the project worth financing? Our answer is yes,” said the newsletter, in a column reprinted on the Seeking Alpha investment website. The column noted that the program has had positive results in Phase 1 tests.

Leave Your Comment

Comments are moderated by SDDT, in accordance with the SDDT Comment Policy, and may not appear on this commentary until they have been reviewed and deemed appropriate for posting. Also, due to the volume of comments we receive, not all comments will be posted.

SDDT Comment Policy: SDDT encourages you to add a comment to this discussion. You may not post any unlawful, threatening, defamatory, obscene, pornographic or other material that would violate the law. All comments should be relevant to the topic and remain respectful of other authors and commenters. You are solely responsible for your own comments, the consequences of posting those comments, and the consequences of any reliance by you on the comments of others. By submitting your comment, you hereby give SDDT the right, but not the obligation, to post, air, edit, exhibit, telecast, cablecast, webcast, re-use, publish, reproduce, use, license, print, distribute or otherwise use your comment(s) and accompanying personal identifying and other information you provide via all forms of media now known or hereafter devised, worldwide, in perpetuity. SDDT Privacy Statement.

User Response
0 UserComments

Leave Your Comment

Comments are moderated by SDDT, in accordance with the SDDT Comment Policy, and may not appear on this commentary until they have been reviewed and deemed appropriate for posting. Also, due to the volume of comments we receive, not all comments will be posted.

SDDT Comment Policy: SDDT encourages you to add a comment to this discussion. You may not post any unlawful, threatening, defamatory, obscene, pornographic or other material that would violate the law. All comments should be relevant to the topic and remain respectful of other authors and commenters. You are solely responsible for your own comments, the consequences of posting those comments, and the consequences of any reliance by you on the comments of others. By submitting your comment, you hereby give SDDT the right, but not the obligation, to post, air, edit, exhibit, telecast, cablecast, webcast, re-use, publish, reproduce, use, license, print, distribute or otherwise use your comment(s) and accompanying personal identifying and other information you provide via all forms of media now known or hereafter devised, worldwide, in perpetuity. SDDT Privacy Statement.

Subscribe Today!